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High density lipoproteins (HDL) were first identified in the late 1940's and early 1950's as the smallest and densest of all the lipoprotein classes (1) . For many years, however, most of the attention of researchers in the lipoprotein field focused on the relationship between plasma low density lipoprotein cholesterol levels and the development of cardiovascular disease, with little consideration being given to HDL, which were regarded as innocent bystanders in the world of cardiovascular disease.
This point of view changed in 1975, with a publication that described an inverse relationship between HDL cholesterol levels and the development of ischemic heart disease (2) . The authors of this report further hypothesized that strategies that increase HDL levels could potentially decrease the incidence of cardiovascular disease (2) . Over the following four decades the association of high HDL cholesterol levels with a reduced incidence of cardiovascular disease was confirmed in multiple human population studies (3, 4) . These findings were also reinforced in preclinical studies which showed that increasing HDL levels in mice by transgenic overexpression of human apolipoprotein A-I, the main HDL apolipoprotein, inhibited atherosclerotic lesion development (5) and that intravenous infusions of HDL into rabbits promoted lesion regression (6).
The positive outcomes of these studies supported the view that pharmacological interventions that increase HDL levels could potentially reduce the morbidity and mortality associated with cardiovascular disease in humans. They also provided an incentive for the development of a range of therapeutic agents designed specifically to increase HDL levels.
Several approaches were employed in order to achieve this goal, including inhibition of the activity of cholesteryl ester transfer protein (CETP), infusion of reconstituted HDL preparations consisting of apoA-I complexed with phospholipids, and infusion of a small molecule agent that increases apoA-I synthesis. The CETP inhibitors, torcetrapib and dalcetrapib, were the first agents designed specifically to increase HDL levels to be 3 investigated in large scale, clinical cardiovascular outcome trials. Although both inhibitors increased HDL cholesterol and apoA-I levels as expected, the outcomes of these studies were disappointing. Neither torcetrapib nor dalcetrapib reduced cardiovascular events, and torcetrapib caused harm, possibly because of off-target effects (7, 8) In summary, this review series emphasizes the fact that strategies that target HDL should continue to be considered as a means of reducing cardiovascular risk and decreasing the morbidity and mortality associated with cardiovascular disease. When considered together, these review articles also serve as a timely reminder that, while knowledge of HDL biology has progressed significantly in recent years, there is likely still much to be learned before this information can be translated into effective therapeutic interventions.
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